Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.

Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...